Metacrine Revenue and Competitors
Estimated Revenue & Valuation
- Metacrine's estimated annual revenue is currently $1.4M per year.
- Metacrine's estimated revenue per employee is $77,500
- Metacrine's total funding is $173M.
Employee Data
- Metacrine has 18 Employees.
- Metacrine grew their employee count by -33% last year.
Metacrine Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $15.3M | 14 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.5M | 29 | -6% | N/A | N/A |
#10 | $9.6M | 62 | -7% | N/A | N/A |
What Is Metacrine?
Metacrine is a privately held biotech company ?founded in 2015 on technology licensed from the ?laboratory of Dr. Ronald Evans, a world leader in? nuclear hormone receptors and Howard Hughes?Medical Institute Investigator at the Salk Institute. Metacrine will leverage two mechanistically distinct programs to target diabetes, steatohepatitis and other metabolic and liver disorders.
keywords:N/A
$173M
Total Funding
18
Number of Employees
$1.4M
Revenue (est)
-33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Metacrine's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Medical Officer | |
2 | Executive Director | |
3 | Director Clinical Operations | |
4 | VP Clinical Operations | |
5 | Research Scientist | |
6 | Manager, Facilities and Purchasing | |
7 | EVP Human Resources | |
8 | Accounting Manager | |
9 | Scientist |
Metacrine News
Metacrine, Inc. (NASDAQ:MTCR) CEO Preston Klassen Sells 44,748 Shares. Posted by admin on Apr 20th, 2022. Share on Twitter Share on Facebook Share on...
Metacrine, Inc. is a clinical-stage biopharmaceutical company developing differentiated therapies to treat gastrointestinal diseases. Metacrine...
Metacrine, Inc. is a clinical-stage biopharmaceutical company developing differentiated therapies to treat gastrointestinal diseases. Metacrine...
A Rich Heyman-backed startup focusing on NASH treatments, as well as other liver, GI and metabolic diseases, is set to start trading Wednesday and join the already-loaded class of 2020 biotech IPOs. Metacrine has raised $85 million for its public offering after priced shares a ...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.4M | 18 | -18% | N/A |
#2 | $1.9M | 18 | -40% | N/A |
#3 | $2.2M | 18 | N/A | N/A |
#4 | $1.6M | 18 | N/A | N/A |
#5 | $3.5M | 18 | N/A | N/A |